UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044503
Receipt number R000050842
Scientific Title Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Date of disclosure of the study information 2021/06/26
Last modified on 2021/10/12 16:39:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.

Acronym

Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.

Scientific Title

Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.

Scientific Title:Acronym

Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.

Region

Japan


Condition

Condition

Healthy Adults

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the minerals absorption effect when mulberry leaf green juice and baby oligo with minerals are taken by adults aged more than 20 years old and less than 65 years old.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Urinary calcium, urinary magnesium, urinary iron and urinary zinc content.

Key secondary outcomes

Urinary calcium/creatinine ratio, Urinary magnesium/creatinine ratio, Urinary iron/creatinine ratio, Urinary zinc/creatinine ratio, Urinary hydroxyproline content.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.
Washout for 1week or more.
Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.

Interventions/Control_2

Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.

Interventions/Control_3

Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.
Washout for 1week or more.
Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Healthy Japanese who are more than 20 years old and less than 65 years old.

Key exclusion criteria

1.Persons who have chronic illness, receiving medication, have a serious disease history
2.Persons who are allergic to the test food
3.Persons who usually take a large amount of test food
4.Persons who usually take medicine, specified health food, healthy food that may affect mineral absorption.
5.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam
6.Persons who were judged as inappropriate for study participants by the principal investigator
7.Persons who are pregnant, planning or hoping to be pregnant during the study period, breastfeeding

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Nozomi
Middle name
Last name Ando

Organization

Natural Science Co.,Ltd.

Division name

Research and Development Department

Zip code

136-0073

Address

3-4-27 Kitasuna, Koto-ku, Tokyo 136-0073, JAPAN

TEL

03-5665-2311

Email

ando@natural-s.jp


Public contact

Name of contact person

1st name Kosei
Middle name
Last name Nishikawa

Organization

Healthcare Systems Co., Ltd.

Division name

Research and Development Department

Zip code

105-0004

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

TEL

03-6809-2722

Homepage URL


Email

nishikawa@hc-sys.jp


Sponsor or person

Institute

Healthcare Systems Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Healthcare Systems Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Healthcare Systems Co., Ltd.

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

Tel

03-6809-2722

Email

soumu@hc-sys.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 06 Month 01 Day

Date of IRB

2021 Year 06 Month 01 Day

Anticipated trial start date

2021 Year 06 Month 30 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 06 Month 11 Day

Last modified on

2021 Year 10 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050842


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name